{"id":"NCT01302392","sponsor":"Amgen","briefTitle":"A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma","officialTitle":"A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2014-07","completion":"2015-09","firstPosted":"2011-02-24","resultsPosted":"2015-08-04","lastUpdate":"2017-05-02"},"enrollment":315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Carfilzomib","otherNames":["PR-171"]},{"type":"DRUG","name":"Best Supportive Care","otherNames":[]}],"arms":[{"label":"Best Supportive Care","type":"ACTIVE_COMPARATOR"},{"label":"Carfilzomib","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for subjects with multiple myeloma who have received all available approved treatment options and may therefore be considered candidates for palliative care.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.","effectByArm":[{"arm":"Best Supportive Care","deltaMin":10,"sd":null},{"arm":"Carfilzomib","deltaMin":10.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4172"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":68,"countries":["Australia","Austria","Belgium","Czechia","France","Germany","Greece","Hungary","Israel","Italy","New Zealand","Poland","Russia","Serbia","Slovakia","South Korea","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["27416912","22992303"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":78,"n":153},"commonTop":["Anaemia","Thrombocytopenia","Pyrexia","Fatigue","Asthenia"]}}